Targeted hepatitis C screening among ex-injection drug users in the community

Background and Aim Chronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among injection drug users (IDUs) but is often undiagnosed because they represent an underprivileged group that faces multiple barrier...

Full description

Saved in:
Bibliographic Details
Published inJournal of gastroenterology and hepatology Vol. 29; no. 1; pp. 116 - 120
Main Authors Wong, Vincent Wai-Sun, Wong, Grace Lai-Hung, Chim, Angel Mei-Ling, Cheng, Tsz-Fai, Cheung, Shirley Wing-Yan, Lai, Carol Man-Sze, Szeto, Kylie Joan-Yi, Tsang, Sharon, Wu, Stephen Ho-Chun, Yan, Kenneth Kar-Lung, Hui, Alex Yui, Yiu, Desmond Chi-Him, Wu, Brian Bing-Ying, Cheung, David, Chung, Cedric Sze-Lai, Lai, Camey Wai-Man, Chan, Henry Lik-Yuen
Format Journal Article
LanguageEnglish
Published Australia Blackwell Publishing Ltd 01.01.2014
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background and Aim Chronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among injection drug users (IDUs) but is often undiagnosed because they represent an underprivileged group that faces multiple barriers to medical care. Here, we report the results of the New Life New Liver Project, which provides targeted HCV screening and education for ex‐IDUs in the community. Methods Patients were recruited through the social worker networks and referrals by fellow ex‐IDUs, and rapid diagnosis was based on point‐of‐care anti‐HCV testing at rehabilitation centers. Results From 2009 to 2012, we served 234 subjects. One hundred thirty (56%) subjects were anti‐HCV positive. The number needed to screen to detect one patient with positive anti‐HCV was 1.8 (95% confidence interval, 1.6–2.0). However, only 69 (53%) HCV patients attended subsequent follow‐up at regional hospitals, and 26 (20%) received antiviral therapy. Patients who attended follow‐up were older, had higher education level and more active disease as evidenced by higher alanine aminotransferase, HCV RNA, and liver stiffness measurement by transient elastography. Conclusions Targeted screening in ex‐IDUs is effective in identifying patients with HCV infection in the community. Improvement in the referral system and introduction of interferon‐free regimens are needed to increase treatment uptake.
AbstractList BACKGROUND AND AIMChronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among injection drug users (IDUs) but is often undiagnosed because they represent an underprivileged group that faces multiple barriers to medical care. Here, we report the results of the New Life New Liver Project, which provides targeted HCV screening and education for ex-IDUs in the community.METHODSPatients were recruited through the social worker networks and referrals by fellow ex-IDUs, and rapid diagnosis was based on point-of-care anti-HCV testing at rehabilitation centers.RESULTSFrom 2009 to 2012, we served 234 subjects. One hundred thirty (56%) subjects were anti-HCV positive. The number needed to screen to detect one patient with positive anti-HCV was 1.8 (95% confidence interval, 1.6-2.0). However, only 69 (53%) HCV patients attended subsequent follow-up at regional hospitals, and 26 (20%) received antiviral therapy. Patients who attended follow-up were older, had higher education level and more active disease as evidenced by higher alanine aminotransferase, HCV RNA, and liver stiffness measurement by transient elastography.CONCLUSIONSTargeted screening in ex-IDUs is effective in identifying patients with HCV infection in the community. Improvement in the referral system and introduction of interferon-free regimens are needed to increase treatment uptake.
Background and Aim Chronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among injection drug users (IDUs) but is often undiagnosed because they represent an underprivileged group that faces multiple barriers to medical care. Here, we report the results of the New Life New Liver Project, which provides targeted HCV screening and education for ex‐IDUs in the community. Methods Patients were recruited through the social worker networks and referrals by fellow ex‐IDUs, and rapid diagnosis was based on point‐of‐care anti‐HCV testing at rehabilitation centers. Results From 2009 to 2012, we served 234 subjects. One hundred thirty (56%) subjects were anti‐HCV positive. The number needed to screen to detect one patient with positive anti‐HCV was 1.8 (95% confidence interval, 1.6–2.0). However, only 69 (53%) HCV patients attended subsequent follow‐up at regional hospitals, and 26 (20%) received antiviral therapy. Patients who attended follow‐up were older, had higher education level and more active disease as evidenced by higher alanine aminotransferase, HCV RNA, and liver stiffness measurement by transient elastography. Conclusions Targeted screening in ex‐IDUs is effective in identifying patients with HCV infection in the community. Improvement in the referral system and introduction of interferon‐free regimens are needed to increase treatment uptake.
Chronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among injection drug users (IDUs) but is often undiagnosed because they represent an underprivileged group that faces multiple barriers to medical care. Here, we report the results of the New Life New Liver Project, which provides targeted HCV screening and education for ex-IDUs in the community. Patients were recruited through the social worker networks and referrals by fellow ex-IDUs, and rapid diagnosis was based on point-of-care anti-HCV testing at rehabilitation centers. From 2009 to 2012, we served 234 subjects. One hundred thirty (56%) subjects were anti-HCV positive. The number needed to screen to detect one patient with positive anti-HCV was 1.8 (95% confidence interval, 1.6-2.0). However, only 69 (53%) HCV patients attended subsequent follow-up at regional hospitals, and 26 (20%) received antiviral therapy. Patients who attended follow-up were older, had higher education level and more active disease as evidenced by higher alanine aminotransferase, HCV RNA, and liver stiffness measurement by transient elastography. Targeted screening in ex-IDUs is effective in identifying patients with HCV infection in the community. Improvement in the referral system and introduction of interferon-free regimens are needed to increase treatment uptake.
Chronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among injection drug users (IDUs) but is often undiagnosed because they represent an underprivileged group that faces multiple barriers to medical care. Here, we report the results of the New Life New Liver Project, which provides targeted HCV screening and education for ex-IDUs in the community. Patients were recruited through the social worker networks and referrals by fellow ex-IDUs, and rapid diagnosis was based on point-of-care anti-HCV testing at rehabilitation centers. From 2009 to 2012, we served 234 subjects. One hundred thirty (56%) subjects were anti-HCV positive. The number needed to screen to detect one patient with positive anti-HCV was 1.8 (95% confidence interval, 1.6-2.0). However, only 69 (53%) HCV patients attended subsequent follow-up at regional hospitals, and 26 (20%) received antiviral therapy. Patients who attended follow-up were older, had higher education level and more active disease as evidenced by higher alanine aminotransferase, HCV RNA, and liver stiffness measurement by transient elastography. Targeted screening in ex-IDUs is effective in identifying patients with HCV infection in the community. Improvement in the referral system and introduction of interferon-free regimens are needed to increase treatment uptake.
Abstract Background and Aim Chronic hepatitis C virus ( HCV ) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among injection drug users ( IDUs ) but is often undiagnosed because they represent an underprivileged group that faces multiple barriers to medical care. Here, we report the results of the N ew L ife N ew L iver P roject, which provides targeted HCV screening and education for ex‐ IDUs in the community. Methods Patients were recruited through the social worker networks and referrals by fellow ex‐ IDUs , and rapid diagnosis was based on point‐of‐care anti‐ HCV testing at rehabilitation centers. Results From 2009 to 2012, we served 234 subjects. One hundred thirty (56%) subjects were anti‐ HCV positive. The number needed to screen to detect one patient with positive anti‐ HCV was 1.8 (95% confidence interval, 1.6–2.0). However, only 69 (53%) HCV patients attended subsequent follow‐up at regional hospitals, and 26 (20%) received antiviral therapy. Patients who attended follow‐up were older, had higher education level and more active disease as evidenced by higher alanine aminotransferase, HCV RNA , and liver stiffness measurement by transient elastography. Conclusions Targeted screening in ex‐ IDUs is effective in identifying patients with HCV infection in the community. Improvement in the referral system and introduction of interferon‐free regimens are needed to increase treatment uptake.
Author Wong, Vincent Wai-Sun
Wu, Brian Bing-Ying
Cheng, Tsz-Fai
Szeto, Kylie Joan-Yi
Yiu, Desmond Chi-Him
Lai, Camey Wai-Man
Wong, Grace Lai-Hung
Cheung, David
Hui, Alex Yui
Chan, Henry Lik-Yuen
Yan, Kenneth Kar-Lung
Lai, Carol Man-Sze
Wu, Stephen Ho-Chun
Chung, Cedric Sze-Lai
Tsang, Sharon
Cheung, Shirley Wing-Yan
Chim, Angel Mei-Ling
Author_xml – sequence: 1
  givenname: Vincent Wai-Sun
  surname: Wong
  fullname: Wong, Vincent Wai-Sun
  organization: Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
– sequence: 2
  givenname: Grace Lai-Hung
  surname: Wong
  fullname: Wong, Grace Lai-Hung
  organization: Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
– sequence: 3
  givenname: Angel Mei-Ling
  surname: Chim
  fullname: Chim, Angel Mei-Ling
  organization: Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
– sequence: 4
  givenname: Tsz-Fai
  surname: Cheng
  fullname: Cheng, Tsz-Fai
  organization: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
– sequence: 5
  givenname: Shirley Wing-Yan
  surname: Cheung
  fullname: Cheung, Shirley Wing-Yan
  organization: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
– sequence: 6
  givenname: Carol Man-Sze
  surname: Lai
  fullname: Lai, Carol Man-Sze
  organization: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
– sequence: 7
  givenname: Kylie Joan-Yi
  surname: Szeto
  fullname: Szeto, Kylie Joan-Yi
  organization: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
– sequence: 8
  givenname: Sharon
  surname: Tsang
  fullname: Tsang, Sharon
  organization: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
– sequence: 9
  givenname: Stephen Ho-Chun
  surname: Wu
  fullname: Wu, Stephen Ho-Chun
  organization: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
– sequence: 10
  givenname: Kenneth Kar-Lung
  surname: Yan
  fullname: Yan, Kenneth Kar-Lung
  organization: Private gastroenterologists, Hong Kong
– sequence: 11
  givenname: Alex Yui
  surname: Hui
  fullname: Hui, Alex Yui
  organization: Private gastroenterologists, Hong Kong
– sequence: 12
  givenname: Desmond Chi-Him
  surname: Yiu
  fullname: Yiu, Desmond Chi-Him
  organization: Private gastroenterologists, Hong Kong
– sequence: 13
  givenname: Brian Bing-Ying
  surname: Wu
  fullname: Wu, Brian Bing-Ying
  organization: Private gastroenterologists, Hong Kong
– sequence: 14
  givenname: David
  surname: Cheung
  fullname: Cheung, David
  organization: Caritas Lok Heep Club, Hong Kong
– sequence: 15
  givenname: Cedric Sze-Lai
  surname: Chung
  fullname: Chung, Cedric Sze-Lai
  organization: Caritas Lok Heep Club, Hong Kong
– sequence: 16
  givenname: Camey Wai-Man
  surname: Lai
  fullname: Lai, Camey Wai-Man
  organization: Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
– sequence: 17
  givenname: Henry Lik-Yuen
  surname: Chan
  fullname: Chan, Henry Lik-Yuen
  email: hlychan@cuhk.edu.hk
  organization: Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24033786$$D View this record in MEDLINE/PubMed
BookMark eNqNkE1vEzEQQC1URNPCgT9Q-VgO29rrj9k9VoGkoAJSVcTR8tqTxGnWm9q7Ivn3LKTtrVLnMHN58w7vhBzFLiIhHzm74ONcrperC14Kpd6QCZeSFRykPiITVnFV1ILXx-Qk5zVjTDJQ78hxKZkQUOkJ-X5n0xJ79HSFW9uHPmQ6pdklxBjiktq2GzfuihDX6PrQRerTsKRDxpRpiLRfIXVd2w4x9Pv35O3CbjJ-eLyn5Nfsy930urj5Of86vbopnNSlKngDCj1XrIHSe9c0HB1gg3UjnKyVYLAAaEDUznqpEcoKPTiPtgItLVhxSs4P3m3qHgbMvWlDdrjZ2IjdkA2Xta5qppV6DcoAatBsRD8dUJe6nBMuzDaF1qa94cz8C23G0OZ_6JE9e9QOTYv-mXwqOwKXB-BP2OD-ZZP5Nr9-UhaHj5B73D1_2HRvNAhQ5vePuVFy9pnN-K25FX8BJ4WYTw
CitedBy_id crossref_primary_10_1016_j_drugpo_2017_05_019
crossref_primary_10_1038_s41575_018_0026_5
crossref_primary_10_1186_s12876_020_01277_0
crossref_primary_10_3748_wjg_v27_i16_1728
crossref_primary_10_1093_ofid_ofw065
crossref_primary_10_3748_wjg_v22_i33_7604
crossref_primary_10_1016_j_drugalcdep_2014_12_027
crossref_primary_10_9778_cmajo_20140024
crossref_primary_10_1007_s12072_015_9630_4
crossref_primary_10_1111_jgh_14003
crossref_primary_10_1111_jvh_12760
crossref_primary_10_3109_14659891_2014_1000986
crossref_primary_10_1111_jgh_14622
crossref_primary_10_1016_j_drugpo_2015_07_003
crossref_primary_10_1111_liv_13949
crossref_primary_10_1111_liv_13926
crossref_primary_10_1016_j_antiviral_2014_01_002
crossref_primary_10_1080_14737159_2017_1400385
crossref_primary_10_1111_apt_12745
crossref_primary_10_1016_j_drugpo_2018_08_011
crossref_primary_10_1038_nrgastro_2017_106
crossref_primary_10_1016_S2468_1253_17_30075_4
crossref_primary_10_1093_ofid_ofv101
crossref_primary_10_1111_jgh_12890
crossref_primary_10_35772_ghm_2021_01049
crossref_primary_10_1007_s11606_015_3209_6
crossref_primary_10_1007_s10461_015_1074_2
Cites_doi 10.1016/j.cgh.2008.02.038
10.1136/gut.2006.111302
10.7326/0003-4819-156-4-201202210-00004
10.1056/NEJMoa1014463
10.1056/NEJMoa1013086
10.1056/NEJMoa1104430
10.1056/NEJMoa1208953
10.1016/S0140-6736(10)61497-3
10.1056/NEJMra1213651
10.7326/0003-4819-144-10-200605160-00010
10.1056/NEJMoa1010494
10.7326/0003-4819-157-8-201210160-00006
10.1056/NEJMoa1012912
10.1056/NEJMoa0908014
10.1056/NEJMoa1214853
10.1111/jgh.12041
10.7326/0003-4819-149-6-200809160-00006
10.1016/S0140-6736(11)61097-0
10.1016/j.jhep.2011.02.023
10.1056/NEJMp1302973
10.1053/jhep.2001.25882
10.1007/s10620-010-1412-1
10.1056/NEJMoa1009482
10.1001/jama.280.6.547
10.7326/0003-4819-157-9-201211060-00529
10.7326/0003-4819-158-5-201303050-00005
10.1002/hep.22759
10.1086/427449
10.1038/ajg.2013.50
10.1056/NEJMoa1214854
ContentType Journal Article
Copyright 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd
2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.
Copyright_xml – notice: 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd
– notice: 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.
DBID BSCLL
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
7U9
H94
DOI 10.1111/jgh.12355
DatabaseName Istex
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Virology and AIDS Abstracts
DatabaseTitleList MEDLINE - Academic

AIDS and Cancer Research Abstracts
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1440-1746
EndPage 120
ExternalDocumentID 10_1111_jgh_12355
24033786
JGH12355
ark_67375_WNG_54FD0F1R_R
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Hong Kong
GeographicLocations_xml – name: Hong Kong
GrantInformation_xml – fundername: Food and Health Bureau of the Government of the Hong Kong SAR
  funderid: 6902849
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1OB
1OC
29K
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAVGM
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABHUG
ABJNI
ABPTK
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXME
ACXQS
ADAWD
ADBBV
ADBTR
ADDAD
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFVGU
AFZJQ
AGJLS
AHBTC
AHEFC
AIACR
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
D-I
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DTERQ
DU5
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
KMS
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
UB1
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WOHZO
WOQ
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YFH
ZZTAW
~IA
~WT
AITYG
HGLYW
OIG
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
7U9
H94
ID FETCH-LOGICAL-c4625-1b75ed150b72ddcbb1ec7ebe9b3c495307f77b739cad46e728ed7cdea8764a7a3
IEDL.DBID DR2
ISSN 0815-9319
IngestDate Fri Aug 16 01:39:22 EDT 2024
Fri Aug 16 05:04:42 EDT 2024
Fri Aug 23 00:55:36 EDT 2024
Sat Sep 28 07:53:15 EDT 2024
Sat Aug 24 00:55:15 EDT 2024
Wed Jan 17 05:02:36 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords patient compliance
interferons
opioid-related disorders
elasticity
liver cirrhosis
Language English
License 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4625-1b75ed150b72ddcbb1ec7ebe9b3c495307f77b739cad46e728ed7cdea8764a7a3
Notes ark:/67375/WNG-54FD0F1R-R
ArticleID:JGH12355
istex:F65930BB5201A8DBBB0E277F2C7DAAB55843A3FD
Food and Health Bureau of the Government of the Hong Kong SAR - No. 6902849
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 24033786
PQID 1490779760
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_1496890655
proquest_miscellaneous_1490779760
crossref_primary_10_1111_jgh_12355
pubmed_primary_24033786
wiley_primary_10_1111_jgh_12355_JGH12355
istex_primary_ark_67375_WNG_54FD0F1R_R
PublicationCentury 2000
PublicationDate January 2014
PublicationDateYYYYMMDD 2014-01-01
PublicationDate_xml – month: 01
  year: 2014
  text: January 2014
PublicationDecade 2010
PublicationPlace Australia
PublicationPlace_xml – name: Australia
PublicationTitle Journal of gastroenterology and hepatology
PublicationTitleAlternate J Gastroenterol Hepatol
PublicationYear 2014
Publisher Blackwell Publishing Ltd
Publisher_xml – name: Blackwell Publishing Ltd
References Thomas DL. Curing hepatitis C with pills: a step toward global control. Lancet 2010; 376: 1441-1442.
Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann. Intern. Med. 2012; 157: 558-566.
Strathdee SA, Palepu A, Cornelisse PG et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280: 547-549.
Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 2013; 368: 1867-1877.
Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann. Intern. Med. 2012; 156: 271-278.
Visconti AJ, Doyle JS, Weir A, Shiell AM, Hellard ME. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia. J. Gastroenterol. Hepatol. 2013; 28: 707-716.
Wong GL, Wong VW, Choi PC et al. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin. Gastroenterol. Hepatol. 2008; 6: 1027-1035.
Yan KK, Wong GL, Wong VW, Chan HL. Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital. Dig. Dis. Sci. 2010; 55: 3541-3547.
European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 2011; 55: 245-264.
Mallet V, Gilgenkrantz H, Serpaggi J et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann. Intern. Med. 2008; 149: 399-403.
Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin. Infect. Dis. 2005; 40 (Suppl. 5): S336-338.
Lok AS, Gardiner DF, Lawitz E et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 2012; 366: 216-224.
Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188-193.
Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
Gane EJ, Stedman CA, Hyland RH et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 2013; 368: 34-44.
Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N. Engl. J. Med. 2013; 368: 1907-1917.
Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207-1217.
Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405-2416.
Spaulding AC, Weinbaum CM, Lau DT et al. A framework for management of hepatitis C in prisons. Ann. Intern. Med. 2006; 144: 762-769.
Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1195-1206.
Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 2011; 365: 1014-1024.
Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 2013; 368: 1878-1887.
Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann. Intern. Med. 2013; 158: 329-337.
Nelson PK, Mathers BM, Cowie B et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-583.
Sears DM, Cohen DC, Ackerman K, Ma JE, Song J. Birth cohort screening for chronic hepatitis during colonoscopy appointments. Am. J. Gastroenterol. 2013; 108: 981-989.
Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann. Intern. Med. 2012; 157: 817-822.
Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N. Engl. J. Med. 2013; 368: 1859-1861.
Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 2417-2428.
Fraquelli M, Rigamonti C, Casazza G et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-973.
McHutchison JG, Manns MP, Muir AJ et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 2010; 362: 1292-1303.
2010; 55
2011; 378
1998; 280
2012; 156
2013; 28
2012; 157
2012; 366
2013; 108
2013; 368
2010; 376
2005; 40
2013; 158
2011; 55
2010; 362
2008; 149
2008; 6
2013
2001; 34
2007; 56
2009; 49
2011; 365
2006; 144
2011; 364
e_1_2_6_32_1
e_1_2_6_10_1
e_1_2_6_31_1
e_1_2_6_30_1
e_1_2_6_19_1
e_1_2_6_13_1
e_1_2_6_14_1
e_1_2_6_11_1
e_1_2_6_12_1
e_1_2_6_17_1
e_1_2_6_18_1
e_1_2_6_15_1
e_1_2_6_16_1
e_1_2_6_21_1
e_1_2_6_20_1
e_1_2_6_9_1
e_1_2_6_8_1
e_1_2_6_5_1
e_1_2_6_4_1
e_1_2_6_7_1
e_1_2_6_6_1
e_1_2_6_25_1
e_1_2_6_24_1
e_1_2_6_3_1
e_1_2_6_23_1
e_1_2_6_2_1
e_1_2_6_22_1
e_1_2_6_29_1
e_1_2_6_28_1
e_1_2_6_27_1
e_1_2_6_26_1
References_xml – volume: 55
  start-page: 3541
  year: 2010
  end-page: 3547
  article-title: Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital
  publication-title: Dig. Dis. Sci.
– volume: 368
  start-page: 1878
  year: 2013
  end-page: 1887
  article-title: Sofosbuvir for previously untreated chronic hepatitis C infection
  publication-title: N. Engl. J. Med.
– volume: 364
  start-page: 2417
  year: 2011
  end-page: 2428
  article-title: Telaprevir for retreatment of HCV infection
  publication-title: N. Engl. J. Med.
– volume: 40
  start-page: S336
  issue: Suppl. 5
  year: 2005
  end-page: 338
  article-title: Follow‐up studies of treatment for hepatitis C virus infection among injection drug users
  publication-title: Clin. Infect. Dis.
– volume: 55
  start-page: 245
  year: 2011
  end-page: 264
  article-title: EASL Clinical Practice Guidelines: management of hepatitis C virus infection
  publication-title: J. Hepatol.
– volume: 56
  start-page: 968
  year: 2007
  end-page: 973
  article-title: Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease
  publication-title: Gut
– volume: 156
  start-page: 271
  year: 2012
  end-page: 278
  article-title: The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007
  publication-title: Ann. Intern. Med.
– volume: 368
  start-page: 1867
  year: 2013
  end-page: 1877
  article-title: Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
  publication-title: N. Engl. J. Med.
– volume: 366
  start-page: 216
  year: 2012
  end-page: 224
  article-title: Preliminary study of two antiviral agents for hepatitis C genotype 1
  publication-title: N. Engl. J. Med.
– volume: 364
  start-page: 2405
  year: 2011
  end-page: 2416
  article-title: Telaprevir for previously untreated chronic hepatitis C virus infection
  publication-title: N. Engl. J. Med.
– volume: 362
  start-page: 1292
  year: 2010
  end-page: 1303
  article-title: Telaprevir for previously treated chronic HCV infection
  publication-title: N. Engl. J. Med.
– volume: 34
  start-page: 188
  year: 2001
  end-page: 193
  article-title: Treatment of hepatitis C infection in injection drug users
  publication-title: Hepatology
– volume: 6
  start-page: 1027
  year: 2008
  end-page: 1035
  article-title: Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases
  publication-title: Clin. Gastroenterol. Hepatol.
– volume: 368
  start-page: 34
  year: 2013
  end-page: 44
  article-title: Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C
  publication-title: N. Engl. J. Med.
– volume: 365
  start-page: 1014
  year: 2011
  end-page: 1024
  article-title: Response‐guided telaprevir combination treatment for hepatitis C virus infection
  publication-title: N. Engl. J. Med.
– volume: 28
  start-page: 707
  year: 2013
  end-page: 716
  article-title: Assessing the cost‐effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia
  publication-title: J. Gastroenterol. Hepatol.
– volume: 368
  start-page: 1859
  year: 2013
  end-page: 1861
  article-title: Hepatitis C in the United States
  publication-title: N. Engl. J. Med.
– volume: 158
  start-page: 329
  year: 2013
  end-page: 337
  article-title: Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta‐analysis of observational studies
  publication-title: Ann. Intern. Med.
– volume: 280
  start-page: 547
  year: 1998
  end-page: 549
  article-title: Barriers to use of free antiretroviral therapy in injection drug users
  publication-title: JAMA
– volume: 149
  start-page: 399
  year: 2008
  end-page: 403
  article-title: Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C
  publication-title: Ann. Intern. Med.
– volume: 108
  start-page: 981
  year: 2013
  end-page: 989
  article-title: Birth cohort screening for chronic hepatitis during colonoscopy appointments
  publication-title: Am. J. Gastroenterol.
– volume: 368
  start-page: 1907
  year: 2013
  end-page: 1917
  article-title: Current and future therapies for hepatitis C virus infection
  publication-title: N. Engl. J. Med.
– volume: 376
  start-page: 1441
  year: 2010
  end-page: 1442
  article-title: Curing hepatitis C with pills: a step toward global control
  publication-title: Lancet
– volume: 378
  start-page: 571
  year: 2011
  end-page: 583
  article-title: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews
  publication-title: Lancet
– volume: 364
  start-page: 1195
  year: 2011
  end-page: 1206
  article-title: Boceprevir for untreated chronic HCV genotype 1 infection
  publication-title: N. Engl. J. Med.
– volume: 157
  start-page: 817
  year: 2012
  end-page: 822
  article-title: Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention
  publication-title: Ann. Intern. Med.
– volume: 157
  start-page: 558
  year: 2012
  end-page: 566
  article-title: Accuracy of rapid and point‐of‐care screening tests for hepatitis C: a systematic review and meta‐analysis
  publication-title: Ann. Intern. Med.
– volume: 49
  start-page: 1335
  year: 2009
  end-page: 1374
  article-title: American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update
  publication-title: Hepatology
– volume: 144
  start-page: 762
  year: 2006
  end-page: 769
  article-title: A framework for management of hepatitis C in prisons
  publication-title: Ann. Intern. Med.
– volume: 364
  start-page: 1207
  year: 2011
  end-page: 1217
  article-title: Boceprevir for previously treated chronic HCV genotype 1 infection
  publication-title: N. Engl. J. Med.
– year: 2013
– ident: e_1_2_6_15_1
  doi: 10.1016/j.cgh.2008.02.038
– ident: e_1_2_6_16_1
  doi: 10.1136/gut.2006.111302
– ident: e_1_2_6_2_1
  doi: 10.7326/0003-4819-156-4-201202210-00004
– ident: e_1_2_6_25_1
  doi: 10.1056/NEJMoa1014463
– ident: e_1_2_6_28_1
  doi: 10.1056/NEJMoa1013086
– ident: e_1_2_6_29_1
  doi: 10.1056/NEJMoa1104430
– ident: e_1_2_6_30_1
  doi: 10.1056/NEJMoa1208953
– ident: e_1_2_6_14_1
  doi: 10.1016/S0140-6736(10)61497-3
– ident: e_1_2_6_3_1
  doi: 10.1056/NEJMra1213651
– ident: e_1_2_6_20_1
  doi: 10.7326/0003-4819-144-10-200605160-00010
– ident: e_1_2_6_24_1
  doi: 10.1056/NEJMoa1010494
– ident: e_1_2_6_21_1
  doi: 10.7326/0003-4819-157-8-201210160-00006
– ident: e_1_2_6_23_1
  doi: 10.1056/NEJMoa1012912
– ident: e_1_2_6_17_1
– ident: e_1_2_6_26_1
  doi: 10.1056/NEJMoa0908014
– ident: e_1_2_6_32_1
  doi: 10.1056/NEJMoa1214853
– ident: e_1_2_6_10_1
  doi: 10.1111/jgh.12041
– ident: e_1_2_6_4_1
  doi: 10.7326/0003-4819-149-6-200809160-00006
– ident: e_1_2_6_7_1
  doi: 10.1016/S0140-6736(11)61097-0
– ident: e_1_2_6_12_1
  doi: 10.1016/j.jhep.2011.02.023
– ident: e_1_2_6_6_1
  doi: 10.1056/NEJMp1302973
– ident: e_1_2_6_8_1
  doi: 10.1053/jhep.2001.25882
– ident: e_1_2_6_22_1
  doi: 10.1007/s10620-010-1412-1
– ident: e_1_2_6_27_1
  doi: 10.1056/NEJMoa1009482
– ident: e_1_2_6_13_1
  doi: 10.1001/jama.280.6.547
– ident: e_1_2_6_18_1
  doi: 10.7326/0003-4819-157-9-201211060-00529
– ident: e_1_2_6_5_1
  doi: 10.7326/0003-4819-158-5-201303050-00005
– ident: e_1_2_6_11_1
  doi: 10.1002/hep.22759
– ident: e_1_2_6_9_1
  doi: 10.1086/427449
– ident: e_1_2_6_19_1
  doi: 10.1038/ajg.2013.50
– ident: e_1_2_6_31_1
  doi: 10.1056/NEJMoa1214854
SSID ssj0004075
Score 2.2709913
Snippet Background and Aim Chronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly...
Chronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly prevalent among...
Abstract Background and Aim Chronic hepatitis C virus ( HCV ) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is...
BACKGROUND AND AIMChronic hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. It is highly...
SourceID proquest
crossref
pubmed
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 116
SubjectTerms Alanine Transaminase
Biomarkers
Community Health Services
Community Networks
Drug Users - statistics & numerical data
elasticity
Elasticity Imaging Techniques
Female
Follow-Up Studies
Hepacivirus - genetics
Hepacivirus - immunology
Hepatitis C - diagnosis
Hepatitis C - drug therapy
Hepatitis C - epidemiology
Hepatitis C - prevention & control
Hepatitis C virus
Hong Kong - epidemiology
Humans
interferons
liver cirrhosis
Male
Mass Screening - methods
Middle Aged
opioid-related disorders
patient compliance
Patient Education as Topic
Point-of-Care Systems
RNA, Viral
Severity of Illness Index
Title Targeted hepatitis C screening among ex-injection drug users in the community
URI https://api.istex.fr/ark:/67375/WNG-54FD0F1R-R/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjgh.12355
https://www.ncbi.nlm.nih.gov/pubmed/24033786
https://search.proquest.com/docview/1490779760
https://search.proquest.com/docview/1496890655
Volume 29
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEB6Kgnjx_agvooh42bLtPrKLJ6m2RVChWPQgLMkmfVjYSruF6smf4G_0lzjJPrSiIt5ymCXZzCTzTTLzBeCwIhm3fNszhO-2DZt53MCGNEI0lrJQmceaSunyym207Is7564AJ1ktTMIPkR-4qZWh92u1wBkffV7knW5JFXqqAnNFpKcAUfODOspOSHbR4zmGj3aWsgrpLJ7syylfNKumdfId0JzGrdrx1BbhPhtykm_SL41jXgqfv7A5_vOflmAhBaTkNLGgZSjIaAXmLtMr91W4vtG54lKQrlTZ13FvRKoENxsMgNHtEf1aEZGTt5fXXvSgE7siIobjDlHnHyPSiwhiTBImhSjx0xq0auc31YaRvsKA-sLgyChz6kiBuJHTihAh52UZUlS9z61QJaeatE0pp5YfMmG7klY8KWgoJMN91maUWeswEw0iuQnEE0y9ESlcicCFWSZDWY8Kx_NdjHNcpwgHmT6Cx4RsI8iDlE430FNThCOtqVyCDfsqO406we1VPXDs2plZKzeDZhH2M1UGuGbURQiL5GA8wnDHNylFIGb-KuN6PgI07HAjsYO8R8VhaFHPLcKx1ubPgw0u6g3d2Pq76DbMIyqzk3OeHZiJh2O5i8gn5nvaxN8BRSf93Q
link.rule.ids 315,786,790,1382,27957,27958,46329,46753
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NThsxEB4FIhUuhZa_lJ-6VVVx2WiTXa93JS4ICCFNUikKKhdk2WuTBKSlSjYS5cQj8Iw8CWNvNgUECHHzYVb2emY839ifxwA_qlpIL_JDR0XBmeOLUDrY0E6MxlJRhnlsSym12kH92G-c0JMC7OR3YbL6ENMNN-MZdr02Dm42pB96ea9fNjc96QwU0d2pTag6_4tH-VmZXYx51InQ0iZ1hSyPJ__0UTQqmom9eg5qPkauNvTUFuA0H3TGOLkoj1NZjq-f1HN8718twscJJiW7mRF9goJOPsOH1uTUfQl-dy1dXCvS14aAnQ5GZI_geoM5MEY-Yh8sIvrq7uZ2kJxbbldC1HDcI2YLZEQGCUGYSeLsLkr6bxmOawfdvbozeYgBVYb5kVORjGqF0FGyqlKxlBUdM9R-JL3Y8FNddsaYZF4UC-UHmlVDrVistMCl1hdMeCswm1wmeg1IqIR5JlIFGrGL8FyBsiFTNIwCTHUCWoLvuUL436zeBp_mKb0-t1NTgp9WVVMJMbwwBDVG-Z_2Iad-bd-tVTq8U4JvuS45uo05CxGJvhyPMOOJXMYQi7mvygRhhBgNO1zNDGHaoylj6LEwKMG2VefLg-WNw7ptfHm76FeYq3dbTd48av9ah3kEaX627bMBs-lwrDcRCKVyy9r7PS-XAg4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RkBCXQnm0C7Q1CFVcsspuHDtRT4htWF4LWoHKoZJlx94HSAHtZiXaU38Cv5FfwtjZLAWVCvXmw0R2PDOeb-zPY4CtupEqiGnk6Zh1PCoj5WHDeCkaS01b5rErpXTcYs1zenARXkzB1_IuTFEfYrLhZj3DrdfWwW90508n7_aq9qJn-AZmKAvq1qQb7cfaUbSososhL_RiNLRxWSFH4yk_fRKMZuy83v4NaT4Fri7yJPPwoxxzQTi5qo5yVU1_PSvn-J8_tQBvx4iU7BQm9A6mTLYIs8fjM_clODlzZHGjSc9Y-nXeH5JdgqsNZsAY94h7roiY2_vfd_3s0jG7MqIHoy6xGyBD0s8IgkySFjdR8p_LcJ58O9tteuNnGFBhmB15NcVDoxE4Kl7XOlWqZlKOuo9VkFp2qs87nCsexKnUlBlej4zmqTYSF1oquQxWYDq7zswHIJGW9pFIzQwiFxn4EmUjrsMoZpjosLACm6U-xE1RbUNMspRuT7ipqcAXp6mJhBxcWXoaD8X31p4IadLwk1pbtCuwUapSoNPYkxCZmevREPOd2OcckZj_TxkWxYjQsMP3hR1MerRFDAMesQpsO22-PFhxsNd0jdXXi36G2dNGIo72W4drMIcIjRZ7PuswnQ9G5iOioFx9ctb-ACy1AL0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeted+hepatitis+C+screening+among+ex-injection+drug+users+in+the+community&rft.jtitle=Journal+of+gastroenterology+and+hepatology&rft.au=Wong%2C+Vincent+Wai-Sun&rft.au=Wong%2C+Grace+Lai-Hung&rft.au=Chim%2C+Angel+Mei-Ling&rft.au=Cheng%2C+Tsz-Fai&rft.date=2014-01-01&rft.eissn=1440-1746&rft.volume=29&rft.issue=1&rft.spage=116&rft_id=info:doi/10.1111%2Fjgh.12355&rft_id=info%3Apmid%2F24033786&rft.externalDocID=24033786
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0815-9319&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0815-9319&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0815-9319&client=summon